CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.1% – Here’s What Happened

CRISPR Therapeutics AG (NASDAQ:CRSP)’s share price fell 0.1% on Tuesday . The stock traded as low as $40.94 and last traded at $41.80. 447,191 shares traded hands during trading, a decline of 77% from the average session volume of 1,968,914 shares. The stock had previously closed at $41.85.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CRSP. JMP Securities reiterated a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Chardan Capital reaffirmed a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.38.

CRISPR Therapeutics Stock Performance

The stock has a market capitalization of $3.59 billion, a PE ratio of -14.86 and a beta of 1.68. The stock’s 50-day moving average is $43.88 and its 200 day moving average is $47.38.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the prior year, the firm earned ($1.41) EPS. Analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the sale, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in shares of CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the last quarter. FMR LLC increased its holdings in shares of CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after buying an additional 23,075 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after purchasing an additional 35,196 shares during the period. Baker BROS. Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after acquiring an additional 743,075 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of CRISPR Therapeutics by 0.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock valued at $34,025,000 after acquiring an additional 6,635 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.